MX2015010438A - COMPOSICION DE INHIBIDOR DE IL-1ß Y USO DE LA MISMA. - Google Patents
COMPOSICION DE INHIBIDOR DE IL-1ß Y USO DE LA MISMA.Info
- Publication number
- MX2015010438A MX2015010438A MX2015010438A MX2015010438A MX2015010438A MX 2015010438 A MX2015010438 A MX 2015010438A MX 2015010438 A MX2015010438 A MX 2015010438A MX 2015010438 A MX2015010438 A MX 2015010438A MX 2015010438 A MX2015010438 A MX 2015010438A
- Authority
- MX
- Mexico
- Prior art keywords
- human
- heterodimeric protein
- protein assembly
- 1racp
- mutants
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
Abstract
Se describe una composición terapéutica que se puede usar para tratamiento o prevención de enfermedades en asociación con la modulación de la actividad de IL-1ß humana. En ciertos aspectos, la invención descrita se basa, en la ingeniería de un ensamblaje de proteína heterodimérica que es capaz del enlace a IL-1ß humana y atenuación de su función. El ensamblaje de proteína heterodimérica comprende porciones extracelulares de IL1-R1 humana y de IL-1RAcP humana, o sus fragmentos funcionales. Cada una, la porción IL1-R1 y la porción IL-1RAcP, se fusiona a un mutante distinto de la porción Fc de la Ig Gamma-1 humana. Los dos mutantes Fc distintos en el ensamblaje de proteína heterodimérica se diseñan para favorecer la formación de dímero heteromérico entre los dos mutantes Fc sobre cualquier ensamblaje homomérico. También se proporcionan vectores de expresión de DNA y sistemas de expresión para sobreproducir los polipéptidos en células de mamífero.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2013/026349 WO2014126582A1 (en) | 2013-02-15 | 2013-02-15 | IL-1β INHIBITOR COMPOSITION AND USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015010438A true MX2015010438A (es) | 2016-05-05 |
Family
ID=51354448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015010438A MX2015010438A (es) | 2013-02-15 | 2013-02-15 | COMPOSICION DE INHIBIDOR DE IL-1ß Y USO DE LA MISMA. |
Country Status (16)
| Country | Link |
|---|---|
| EP (2) | EP4050019A1 (es) |
| JP (1) | JP6225197B2 (es) |
| KR (1) | KR101989551B1 (es) |
| CN (1) | CN105431448B (es) |
| AU (1) | AU2013378122B2 (es) |
| BR (1) | BR112015019729B1 (es) |
| DK (1) | DK2956471T3 (es) |
| EA (1) | EA033269B1 (es) |
| FI (1) | FI2956471T3 (es) |
| HK (1) | HK1219281A1 (es) |
| IL (1) | IL240553B (es) |
| MX (1) | MX2015010438A (es) |
| NZ (1) | NZ710900A (es) |
| PH (1) | PH12015501796A1 (es) |
| SG (1) | SG11201506389YA (es) |
| WO (1) | WO2014126582A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ710900A (en) | 2013-02-15 | 2019-09-27 | R Pharm International Llc | Il-1β inhibitor composition and use thereof |
| CN104628870A (zh) * | 2015-02-04 | 2015-05-20 | 中国药科大学 | 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白 |
| CN104725514A (zh) * | 2015-02-06 | 2015-06-24 | 中国药科大学 | 新型il23拮抗剂 |
| EP3638700A4 (en) * | 2017-06-14 | 2021-04-21 | Dingfu Biotarget Co., Ltd | PROTEINOUS HETERODIMER AND USE OF IT |
| JP7301815B2 (ja) | 2017-09-26 | 2023-07-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | インターロイキン－１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療 |
| CN115768787A (zh) * | 2020-05-22 | 2023-03-07 | 阿法姆海外股份有限公司 | IL1-R1衍生的IL-1β抑制剂及其用途 |
| KR20220014531A (ko) * | 2020-07-29 | 2022-02-07 | (주)메디톡스 | 헤테로이량체 Ｆｃ 융합 단백질, 및 관련 조성물, 용도 및 방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| PL2322552T3 (pl) * | 2005-06-21 | 2016-08-31 | Xoma Us Llc | PRZECIWCIAŁA WIĄŻĄCE IL-1β I ICH FRAGMENTY |
| US7666622B2 (en) * | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
| EP2235064B1 (en) * | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| KR20140019385A (ko) * | 2011-03-17 | 2014-02-14 | 라모트 앳 텔-아비브 유니버시티 리미티드 | 이중특이성 및 단일특이성, 비대칭성 항체 및 이의 제조방법 |
| WO2014035361A1 (en) * | 2012-08-26 | 2014-03-06 | R-PHARM, CJSC (Closed Joint Stock Company) | IL-1β INHIBITOR COMPOSITION AND USE THEREOF |
| NZ710900A (en) | 2013-02-15 | 2019-09-27 | R Pharm International Llc | Il-1β inhibitor composition and use thereof |
-
2013
- 2013-02-15 NZ NZ71090013A patent/NZ710900A/en unknown
- 2013-02-15 FI FIEP13875211.8T patent/FI2956471T3/fi active
- 2013-02-15 AU AU2013378122A patent/AU2013378122B2/en active Active
- 2013-02-15 EP EP21208571.6A patent/EP4050019A1/en active Pending
- 2013-02-15 BR BR112015019729-9A patent/BR112015019729B1/pt active IP Right Grant
- 2013-02-15 WO PCT/US2013/026349 patent/WO2014126582A1/en active Application Filing
- 2013-02-15 EA EA201500842A patent/EA033269B1/ru unknown
- 2013-02-15 DK DK13875211.8T patent/DK2956471T3/da active
- 2013-02-15 SG SG11201506389YA patent/SG11201506389YA/en unknown
- 2013-02-15 KR KR1020157025393A patent/KR101989551B1/ko active IP Right Grant
- 2013-02-15 MX MX2015010438A patent/MX2015010438A/es unknown
- 2013-02-15 JP JP2015557984A patent/JP6225197B2/ja active Active
- 2013-02-15 CN CN201380075648.9A patent/CN105431448B/zh active Active
- 2013-02-15 EP EP13875211.8A patent/EP2956471B1/en active Active
-
2015
- 2015-08-12 IL IL240553A patent/IL240553B/en active IP Right Grant
- 2015-08-14 PH PH12015501796A patent/PH12015501796A1/en unknown
-
2016
- 2016-06-23 HK HK16107308.4A patent/HK1219281A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12015501796B1 (en) | 2015-11-09 |
| KR101989551B1 (ko) | 2019-09-30 |
| NZ710900A (en) | 2019-09-27 |
| EP4050019A1 (en) | 2022-08-31 |
| EA033269B1 (ru) | 2019-09-30 |
| DK2956471T3 (da) | 2024-05-21 |
| BR112015019729A2 (pt) | 2017-07-18 |
| BR112015019729B1 (pt) | 2023-01-24 |
| FI2956471T3 (fi) | 2024-05-13 |
| EP2956471A1 (en) | 2015-12-23 |
| CN105431448B (zh) | 2019-08-27 |
| IL240553A0 (en) | 2015-10-29 |
| PH12015501796A1 (en) | 2015-11-09 |
| HK1219281A1 (zh) | 2017-03-31 |
| JP2016513106A (ja) | 2016-05-12 |
| EP2956471A4 (en) | 2019-11-13 |
| WO2014126582A1 (en) | 2014-08-21 |
| EA201500842A1 (ru) | 2016-02-29 |
| EP2956471B1 (en) | 2024-04-10 |
| SG11201506389YA (en) | 2015-09-29 |
| CN105431448A (zh) | 2016-03-23 |
| KR20160048028A (ko) | 2016-05-03 |
| AU2013378122B2 (en) | 2019-05-02 |
| IL240553B (en) | 2021-02-28 |
| JP6225197B2 (ja) | 2017-11-01 |
| AU2013378122A1 (en) | 2015-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501796B1 (en) | IL-1á INHIBITOR COMPOSITION AND USE THEREOF | |
| AU2016370470A8 (en) | Dual controls for therapeutic cell activation or elimination | |
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| MX2020010912A (es) | Proteínas il-15/il-15ra de fusión a fc heterodiméricas y usos de las mismas. | |
| MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
| PH12021550802A1 (en) | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof | |
| MX2019014695A (es) | Proteinas de fusion de interleucina-2 y usos de las mismas. | |
| WO2014164348A3 (en) | Modified caspase polypeptides and uses thereof | |
| AU2017263237A1 (en) | GDF15 fusion proteins and uses thereof | |
| MX2018001532A (es) | Anticuerpos anti-angptl8 y usos de estos. | |
| PH12015501493B1 (en) | Anti-pdgfr-beta antibodies and uses thereof | |
| MX2017014083A (es) | Polipeptido de fusion anti-cancer. | |
| MX2021006017A (es) | Polipeptidos de folistatina y sus usos. | |
| MX2018009524A (es) | Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso. | |
| SG10201808523RA (en) | Il-22 polypeptides and il-22 fc fusion proteins and methods of use | |
| MX2015010749A (es) | Anticuerpos humanos para nav1.7. | |
| MX2018005194A (es) | Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas. | |
| MY188897A (en) | Factor viii compositions and methods of making and using same | |
| MX2020009371A (es) | Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión. | |
| MY184241A (en) | Human antibodies to gfr?3 and methods of use thereof | |
| MX2016010953A (es) | Proteinas de fc multimericas. | |
| WO2014025198A3 (ko) | Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도 | |
| MX2018000548A (es) | Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana. | |
| MX2020006635A (es) | Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma. | |
| MX2018013177A (es) | Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas. |